Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

Status: Recruiting

Eligibility Criteria

Age: Not specified

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

1. Diagnosis: Patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. 2. Patients: Patients of any age and either gender 3. Cord blood product manufactured by the NCBP (at least one, if the graft contains more than one units)

Exclusion Criteria:

1. Patients who are receiving licensed cord blood products (only) 2. Patients who are receiving unlicensed cord blood products from other banks (only) 3. Patients who are transplanted at non-US transplant centers 4. Patients who are receiving cord blood products that will be "manipulated" post-thaw (e.g., ex vivo expansion, incubation in vitro, etc.)

Conditions & Interventions

Interventions:
Biological: unlicensed CBU
Conditions:
Infusion Reactions
Keywords:
cord blood, transplantation, stem cells, adverse event

More Information

Contact(s): Dorothy Sung - dsung@nybc.org
Principal Investigator: McCarty, John, M.
Phase: Phase 2
IRB
Number: HM14815
System ID: NCT01656603
